FIGURE 2.

Network diagram for risk of clinical worsening in randomised controlled trials of pulmonary arterial hypertension treatments. Each node represents a drug or drug combination that has been tested in trials; the size of the nodes is proportional to the number of patients that have received that drug or drug combination; and the thickness of the connecting lines is proportional to the number of trials. PDE5i: phosphodiesterase-5 inhibitor; ERA: endothelin receptor antagonist; inh: inhalation; i.v.: intravenous; s.c.: subcutaneous; PRA: prostacyclin receptor agonist.